VANI
Vivani Medical, Inc.
Price Chart
Latest Quote
$1.35
-0.06 (-4.26%)
Current Price
| Previous Close | $1.41 |
| Open | $1.49 |
| Day High | $1.49 |
| Day Low | $1.34 |
| Volume | 648,644 |
Stock Information
| Shares Outstanding | 86.24M |
| Total Debt | $18.27M |
| Cash Equivalents | $19.75M |
| Net Income | $-27.09M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $113.83M |
| EPS (TTM) | $-0.39 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $112.36M |
| Income | $-27.09M |
| Book/sh | $0.23 |
| Cash/sh | $0.23 |
| Employees | 42 |
Financial Ratios
| Quick Ratio | 3.02 |
| Current Ratio | 3.18 |
| Debt/Eq | 95.76 |
Returns & Margins
| ROA | -44.69% |
| ROE | -176.41% |
Ownership
| Insider Ownership | 57.94% |
| Institutional Ownership | 6.48% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.77 |
| P/B | 5.87 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $3.83 |
Technical Indicators
| SMA20 | $1.30 |
| SMA50 | $1.24 |
| SMA200 | $1.31 |
| RSI | 57.14 |
| ATR | 0.1256 |
| Shares Float | 35.69M |
| Short Float | 1.00% |
| Short Ratio | 2.61 |
| Volatility | 3.29 |
| Rel Volume | 0.44 |
Performance History
| Week | -2.94% |
| Month | +12.82% |
| Quarter | +0.76% |
| 6 Months | +3.94% |
| YTD | +3.94% |
| Year | -18.52% |
| 3 Years | +2.33% |
| 5 Years | -89.42% |
| 10 Years | -98.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $1.32 | 468,600 |
| 2026-07-16 | $1.35 | 650,600 |
| 2026-07-15 | $1.41 | 305,100 |
| 2026-07-14 | $1.40 | 224,600 |
| 2026-07-13 | $1.42 | 628,700 |
| 2026-07-10 | $1.36 | 1,037,300 |
| 2026-07-09 | $1.56 | 1,230,600 |
| 2026-07-08 | $1.60 | 2,321,600 |
| 2026-07-07 | $1.35 | 11,555,400 |
| 2026-07-06 | $1.30 | 198,600 |
| 2026-07-02 | $1.26 | 1,333,900 |
| 2026-07-01 | $1.23 | 49,000 |
| 2026-06-30 | $1.24 | 167,900 |
| 2026-06-29 | $1.21 | 46,800 |
| 2026-06-26 | $1.20 | 164,600 |
| 2026-06-25 | $1.14 | 299,000 |
| 2026-06-24 | $1.22 | 217,100 |
| 2026-06-23 | $1.19 | 247,300 |
| 2026-06-22 | $1.13 | 76,300 |
| 2026-06-18 | $1.15 | 201,900 |
About Vivani Medical, Inc.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
đ° Latest News
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
MarketBeat âĸ 2026-07-15T23:02:22Z
Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal
Simply Wall St. âĸ 2026-07-09T16:12:05Z
Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant
Pharmaceutical Technology âĸ 2026-07-08T11:11:06Z
Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant
Simply Wall St. âĸ 2026-07-07T19:18:04Z
Vivani strikes reverse-merger agreement with ClearOne for BCI business
Medical Device Network âĸ 2026-07-03T11:40:21Z
Why Did CLRO Stock Surge More Than 170% Today?
Stocktwits âĸ 2026-07-02T17:53:59Z
Here's Why We're Watching Vivani Medical's (NASDAQ:VANI) Cash Burn Situation
Simply Wall St. âĸ 2026-05-15T11:21:39Z
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2026-04-03T16:00:04Z
Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright
TipRanks âĸ 2026-04-01T15:51:53Z
Vivani Medical: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-26T20:45:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $27,556,000 | $24,677,000 | $26,965,000 | $21,241,000 |
| Other Income Expense | $947,000 | $1,191,000 | $1,313,000 | $7,352,000 |
| Other Non Operating Income Expenses | $947,000 | $1,191,000 | $1,313,000 | $7,352,000 |
| Operating Expense | $27,556,000 | $24,677,000 | $26,965,000 | $21,241,000 |
| General And Administrative Expense | $9,430,000 | $8,932,000 | $9,997,000 | $7,072,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Normalized Income | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Net Income From Continuing And Discontinued Operation | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Total Operating Income As Reported | $-27,556,000 | $-24,677,000 | $-26,965,000 | $-21,241,000 |
| Net Income Common Stockholders | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Net Income | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Net Income Including Noncontrolling Interests | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Net Income Continuous Operations | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Pretax Income | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Operating Income | $-27,556,000 | $-24,677,000 | $-26,965,000 | $-21,241,000 |
| Special Income Charges | - | - | - | $6,877,000 |
| Per Share | ||||
| Diluted EPS | $-0.43 | $-0.43 | $-0.50 | $-0.36 |
| Basic EPS | $-0.43 | $-0.43 | $-0.50 | $-0.36 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-27,132,000 | $-24,277,000 | $-26,608,000 | $-20,860,000 |
| Reconciled Depreciation | $424,000 | $400,000 | $357,000 | $381,000 |
| EBITDA (Bullshit earnings) | $-27,132,000 | $-24,277,000 | $-26,608,000 | $-20,860,000 |
| EBIT | $-27,556,000 | $-24,677,000 | $-26,965,000 | $-21,241,000 |
| Diluted Average Shares | $62,389,000 | $54,981,000 | $50,853,000 | $38,241,000 |
| Basic Average Shares | $62,389,000 | $54,981,000 | $50,853,000 | $38,241,000 |
| Diluted NI Availto Com Stockholders | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Research And Development | $18,126,000 | $15,745,000 | $16,968,000 | $14,169,000 |
| Selling General And Administration | $9,430,000 | $8,932,000 | $9,997,000 | $7,072,000 |
| Other Gand A | $9,430,000 | $8,932,000 | $9,997,000 | $7,072,000 |
| Total Unusual Items | - | - | - | $6,877,000 |
| Total Unusual Items Excluding Goodwill | - | - | - | $6,877,000 |
| Restructuring And Mergern Acquisition | - | - | - | $-6,877,000 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-07-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $15,730,000 | $17,610,000 | $20,761,000 | $44,308,000 |
| Total Assets | $39,393,000 | $41,561,000 | $45,797,000 | $51,130,000 |
| Total Non Current Assets | $21,495,000 | $21,119,000 | $22,735,000 | $3,602,000 |
| Other Non Current Assets | $1,338,000 | $1,338,000 | $1,390,000 | $1,366,000 |
| Non Current Prepaid Assets | $48,000 | $131,000 | $52,000 | $275,000 |
| Current Assets | $17,898,000 | $20,442,000 | $23,062,000 | $47,528,000 |
| Other Current Assets | $1,012,000 | $1,837,000 | $2,408,000 | $2,452,000 |
| Receivables | $654,000 | $253,000 | $0 | - |
| Taxes Receivable | $654,000 | $253,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $16,232,000 | $18,352,000 | $20,654,000 | $45,076,000 |
| Cash And Cash Equivalents | $16,232,000 | $18,352,000 | $20,654,000 | $45,076,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $18,855,000 | $19,313,000 | $20,696,000 | $955,000 |
| Long Term Debt And Capital Lease Obligation | $17,061,000 | $17,965,000 | $19,313,000 | $0 |
| Current Debt And Capital Lease Obligation | $1,794,000 | $1,348,000 | $1,383,000 | $955,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $23,663,000 | $23,951,000 | $25,036,000 | $6,822,000 |
| Total Non Current Liabilities Net Minority Interest | $17,061,000 | $17,965,000 | $19,313,000 | $0 |
| Current Liabilities | $6,602,000 | $5,986,000 | $5,723,000 | $6,822,000 |
| Payables And Accrued Expenses | $4,443,000 | $4,295,000 | $3,944,000 | $5,210,000 |
| Payables | $1,032,000 | $817,000 | $542,000 | $1,177,000 |
| Accounts Payable | $1,032,000 | $817,000 | $542,000 | $1,177,000 |
| Equity | ||||
| Common Stock Equity | $15,730,000 | $17,610,000 | $20,761,000 | $44,308,000 |
| Total Equity Gross Minority Interest | $15,730,000 | $17,610,000 | $20,761,000 | $44,308,000 |
| Stockholders Equity | $15,730,000 | $17,610,000 | $20,761,000 | $44,308,000 |
| Gains Losses Not Affecting Retained Earnings | $30,000 | $48,000 | $140,000 | $35,000 |
| Other Equity Adjustments | $30,000 | $48,000 | $140,000 | $35,000 |
| Retained Earnings | $-148,533,000 | $-121,924,000 | $-98,438,000 | $-72,786,000 |
| Other | ||||
| Ordinary Shares Number | $76,428,000 | $59,234,688 | $51,031,000 | $50,736,000 |
| Share Issued | $76,428,000 | $59,234,688 | $51,031,000 | $50,736,000 |
| Tangible Book Value | $15,730,000 | $17,610,000 | $20,761,000 | $44,308,000 |
| Invested Capital | $15,730,000 | $17,610,000 | $20,761,000 | $44,308,000 |
| Working Capital | $11,296,000 | $14,456,000 | $17,339,000 | $40,706,000 |
| Capital Lease Obligations | $18,855,000 | $19,313,000 | $20,696,000 | $955,000 |
| Total Capitalization | $15,730,000 | $17,610,000 | $20,761,000 | $44,308,000 |
| Additional Paid In Capital | $164,225,000 | $139,480,000 | $119,054,000 | $117,054,000 |
| Capital Stock | $8,000 | $6,000 | $5,000 | $5,000 |
| Common Stock | $8,000 | $6,000 | $5,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $17,061,000 | $17,965,000 | $19,313,000 | $0 |
| Current Capital Lease Obligation | $1,794,000 | $1,348,000 | $1,383,000 | $955,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $365,000 | $343,000 | $396,000 | $657,000 |
| Current Accrued Expenses | $3,411,000 | $3,478,000 | $3,402,000 | $4,033,000 |
| Net PPE | $20,109,000 | $19,650,000 | $21,345,000 | $1,961,000 |
| Accumulated Depreciation | $-3,054,000 | $-2,641,000 | $-2,442,000 | $-2,411,000 |
| Gross PPE | $23,163,000 | $22,291,000 | $23,787,000 | $4,372,000 |
| Construction In Progress | $1,362,000 | $0 | $299,000 | $0 |
| Other Properties | $21,391,000 | $21,894,000 | $23,127,000 | $4,299,000 |
| Machinery Furniture Equipment | $410,000 | $397,000 | $361,000 | $61,000 |
| Leases | - | - | $0 | $12,000 |
| Properties | - | - | $0 | $0 |
| Line Of Credit | - | - | - | - |
Fetched: 2026-07-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-25,493,000 | $-21,342,000 | $-24,586,000 | $-19,125,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-24,320,000 | $-20,786,000 | $-23,699,000 | $-18,787,000 |
| Cash Flow From Continuing Operating Activities | $-24,320,000 | $-20,786,000 | $-23,699,000 | $-18,787,000 |
| Operating Gains Losses | $-117,000 | - | $121,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,173,000 | $-556,000 | $-887,000 | $-338,000 |
| Investing Cash Flow | $-1,173,000 | $-556,000 | $-887,000 | $-338,000 |
| Cash Flow From Continuing Investing Activities | $-1,173,000 | $-556,000 | $-887,000 | $-338,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-28,000 | - | - | - |
| Issuance Of Capital Stock | $23,291,000 | $18,817,000 | $0 | $16,000 |
| Financing Cash Flow | $23,274,000 | $19,054,000 | $133,000 | $63,390,000 |
| Cash Flow From Continuing Financing Activities | $23,274,000 | $19,054,000 | $133,000 | $63,390,000 |
| Net Common Stock Issuance | $23,263,000 | $18,817,000 | $0 | $16,000 |
| Common Stock Issuance | $23,291,000 | $18,817,000 | $0 | $16,000 |
| Net Other Financing Charges | - | $-189,000 | - | $63,374,000 |
| Other | ||||
| Repayment Of Debt | $-344,000 | $-189,000 | - | - |
| Issuance Of Debt | $355,000 | $426,000 | $0 | - |
| Income Tax Paid Supplemental Data | $0 | $2,000 | $1,000 | $0 |
| End Cash Position | $17,570,000 | $19,690,000 | $21,992,000 | $46,442,000 |
| Beginning Cash Position | $19,690,000 | $21,992,000 | $46,442,000 | $2,178,000 |
| Effect Of Exchange Rate Changes | $99,000 | $-14,000 | $3,000 | $-1,000 |
| Changes In Cash | $-2,219,000 | $-2,288,000 | $-24,453,000 | $44,265,000 |
| Common Stock Payments | $-28,000 | - | - | - |
| Net Issuance Payments Of Debt | $11,000 | $237,000 | $0 | - |
| Net Short Term Debt Issuance | $355,000 | $426,000 | $0 | - |
| Short Term Debt Issuance | $355,000 | $426,000 | $0 | - |
| Net Long Term Debt Issuance | $-344,000 | $-189,000 | - | - |
| Long Term Debt Payments | $-344,000 | $-189,000 | - | - |
| Net PPE Purchase And Sale | $-1,173,000 | $-556,000 | $-887,000 | $-338,000 |
| Purchase Of PPE | $-1,173,000 | $-556,000 | $-887,000 | $-338,000 |
| Change In Working Capital | $229,000 | $354,000 | $-1,293,000 | $338,000 |
| Change In Payables And Accrued Expense | $-278,000 | $116,000 | $-1,557,000 | $814,000 |
| Change In Accrued Expense | $-56,000 | $-132,000 | $-955,000 | $2,755,000 |
| Change In Payable | $-222,000 | $248,000 | $-602,000 | $-1,941,000 |
| Change In Account Payable | $-222,000 | $248,000 | $-602,000 | $-1,941,000 |
| Change In Prepaid Assets | $908,000 | $491,000 | $264,000 | $-476,000 |
| Change In Receivables | $-401,000 | $-253,000 | $0 | - |
| Other Non Cash Items | $269,000 | $276,000 | $904,000 | $-6,913,000 |
| Stock Based Compensation | $1,484,000 | $1,610,000 | $1,864,000 | $1,296,000 |
| Asset Impairment Charge | $0 | $60,000 | $121,000 | - |
| Depreciation Amortization Depletion | $424,000 | $400,000 | $357,000 | $381,000 |
| Depreciation And Amortization | $424,000 | $400,000 | $357,000 | $381,000 |
| Net Foreign Currency Exchange Gain Loss | $-117,000 | $0 | - | - |
| Net Income From Continuing Operations | $-26,609,000 | $-23,486,000 | $-25,652,000 | $-13,889,000 |
| Proceeds From Stock Option Exercised | - | $0 | $133,000 | - |
| Gain Loss On Sale Of PPE | - | - | $121,000 | $0 |
| Change In Other Working Capital | - | - | - | $204,000 |
| Change In Other Current Liabilities | - | - | - | - |
Fetched: 2026-07-13